Business
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) --
About this update from Adma Biologics Inc
[{"type":"text","content":"Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million\nRAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced preliminary estimates for its total revenue for the quarter- and year-ended December 31, 2022. Based on the most current information available to ADMA’s management, including quarter-to-date performance, ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively. This forecasted fourth quarter 2022 revenue represents more than 85% year-over-year growth when compared to $26.4 million of total revenues for the fourth quarter of 2021. About ADMA Biologics, Inc. (ADMA) ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised...